Novartis acquires Tourmaline Bio for $1.4 billion, gaining rights to pacibekitug, the first drug that targets the cause of atherosclerosis rather than its effects. This is Novartis' fifth major deal this year. The total value of the agreements has already exceeded $13 billion.
The WHO has added the injectable drug Yeztugo to its recommendations, with a single injection providing HIV prevention for six months. The decision was made against the backdrop of an expected increase in incidence in Africa following a reduction in aid from the US.
The FDA will not restrict the use of mifepristone until there is new evidence of safety concerns, the agency's chief said. At the same time, a large-scale study showed that one in ten American women experienced serious side effects from this abortifacient - 22 times the rate indicated in the labeling.
Eli Lilly will allocate $27 billion for the construction of four manufacturing facilities in the United States. The decision was made after Donald Trump warned about the potential introduction of tariffs on imported drugs for companies without local production.
Pharmaceutics
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications
Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial.